QuickView for Terazosin (compound)

Terazosine [INN-French]; Terazosin hydrochloride; Terazosin HCl; Abbott 45975; Terazosinum [INN-Latin]; Trazosin HCl; Terazosine; Terazosina [INN-Spanish]

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not us...
show more »

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
show less «

In general, α₁-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α₁-Receptors are 7-transmembrane domain receptors coupled to G proteins, G_q/11. Three α₁-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have ...
show more »

In general, α₁-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α₁-Receptors are 7-transmembrane domain receptors coupled to G proteins, G_q/11. Three α₁-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α_1A (chromosome 8), α_1B (chromosome 5), and α_1D (chromosome 20). Terazosin is the first α₁-receptor antagonist to demonstrate selectivity for the α_1A-receptor. All three receptor subtypes appear to be involved in maintaining vascular tone. The α_1A-receptor maintains basal vascular tone while the α_1B-receptor mediates the vasocontrictory effects of exogenous α₁-agonists. Activation of α₁-receptors activates G_q-proteins, which results in intracellular stimulation of phospholipases C, A₂, and D. This results in mobilization of Ca²⁺ from intracellular stores, activation of mitogen-activated kinase and PI₃ kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting α_1A-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.
show less «